Journal ArticleDOI
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
James R. Berenson,Alan Lichtenstein,Lester Porter,Meletios A. Dimopoulos,Roldolfo Bordoni,Sebastian George,Allan Lipton,Alan Keller,O. F. Ballester,Michael J. Kovacs,Hilary A. Blacklock,Richard Bell,Joseph F. Simeone,Dirk J. Reitsma,Maika Heffernan,John J. Seaman,Robert Knight +16 more
Reads0
Chats0
TLDR
Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.Abstract:
Background Skeletal complications are a major clinical manifestation of multiple myeloma. These complications are caused by soluble factors that stimulate osteoclasts to resorb bone. Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bone resorption. Methods Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy. The patients were stratified according to whether they were receiving first-line (stratum 1) or second-line (stratum 2) antimyeloma chemotherapy at entry into the study. Skeletal events (pathologic fracture, irradiation of or surgery on bone, and spinal cord compression), hypercalcemia (symptoms or a serum calcium concentration >12 mg per deciliter [3.0 mmol per liter]), bone pain, analgesic-drug use, performance status, and quality of life were assessed monthly. Results Among 392 treated patients, th...read more
Citations
More filters
Journal ArticleDOI
Multiple myeloma
Noopur Raje,Kenneth C. Anderson +1 more
TL;DR: The use of bisphosphonates in patients with multiple myeloma (MM) has clearly demonstrated benefit and reduced morbidity associated with bone disease, but all patients with MM ultimately relapse and succumb to their disease.
Journal ArticleDOI
American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.
Salvatore L. Ruggiero,Thomas B. Dodson,John Fantasia,Reginald Goodday,Tara Aghaloo,Bhoomi Mehrotra,Felice O'Ryan +6 more
TL;DR: The American Association of Oral and Maxillofacial Surgeons (AAOMS) developed guidelines for medication-related osteonecrosis of the jaw (MRONJ) in 2007 and 2009 as mentioned in this paper.
Journal ArticleDOI
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Robert A. Kyle,Morie A. Gertz,Thomas E. Witzig,John A. Lust,Martha Q. Lacy,Angela Dispenzieri,Rafael Fonseca,S. Vincent Rajkumar,Janice R. Offord,Dirk R. Larson,Matthew E. Plevak,Terry M. Therneau,Philip R. Greipp +12 more
TL;DR: Multivariate analysis revealed that age, plasma cell labeling index, low platelet count, serum albumin value, and the log of the creatinine value were the most important prognostic factors for newly diagnosed multiple myeloma.
Journal ArticleDOI
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
TL;DR: In view of the current trend of increasing and widespread use of chronic bisphosphonate therapy, the observation of an associated risk of osteonecrosis of the jaw should alert practitioners to monitor for this previously unrecognized potential complication.
Journal ArticleDOI
American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws—2009 Update
Salvatore L. Ruggiero,Thomas B. Dodson,Leon A. Assael,Regina Landesberg,Robert E. Marx,Bhoomi Mehrotra +5 more
TL;DR: This update contains revisions to the diagnosis and staging and management strategies and highlights the status of basic science research.
References
More filters
Journal ArticleDOI
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
TL;DR: Initial staging can be quantitatively related to followup using tumor cell mass changes calculated from changes in M‐component production, and should lead to improved study design and analysis in large clinical trials of therapy for multiple myeloma.
Book
Manual for Staging of Cancer
TL;DR: Part 1 General information on cancer staging and end-results reporting: purposes and principles of staging reporting of cancer survival and end results are explained.
Journal ArticleDOI
Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.
Walter O. Spitzer,Walter O. Spitzer,Annette J. Dobson,Annette J. Dobson,Jane Hall,Jane Hall,Esther Chesterman,Esther Chesterman,John Levi,John Levi,Richard Shepherd,Richard Shepherd,Renaldo N. Battista,Renaldo N. Battista,Barry R. Catchlove,Barry R. Catchlove +15 more
TL;DR: The aim has been to provide a new measure that can help physicians assess the relative benefits and risks of various treatments for serious illness and of supportive programs such as palliative care or hospice service.
Journal ArticleDOI
Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone.
TL;DR: The bone replacement process in the adult skeleton is known as remodeling, and when bone is removed by osteoclasts, new bone is laid down by osteoblasts in the same place, because the load bearing requirement is unchanged.
Journal Article
Multiple myeloma: review of 869 cases.
TL;DR: A review of 869 cases of multiple myeloma seen at the Mayo Clinic from 1960 through 1971 revealed that 98% of patients were 40 years of age or older and that 61% of them were males.